trending Market Intelligence /marketintelligence/en/news-insights/trending/be9TPmmxwM1J5sN8ymNXaQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Calif.-based AnaptysBio prices IPO

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Calif.-based AnaptysBio prices IPO

AnaptysBio Inc. priced its initial public offering at $15 apiece.

The Calif.-based biotechnology company is looking to issue 5 million shares once it goes public. AnaptysBio has also granted underwriters a 30-day option to purchase up to an additional 750,000 of the shares offered.

The offering is expected to close Jan. 31.

Credit Suisse and Stifel are acting as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow are acting as co-managers.

AnaptysBio is developing treatments for inflammation and cancers.